<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; pressure</title>
	<atom:link href="http://www.tapanray.in/tag/pressure/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Continues ‘The Cat And Mouse Game’ In Pharma Business?</title>
		<link>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=continues-the-cat-and-mouse-game-in-pharma-business</link>
		<comments>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/#comments</comments>
		<pubDate>Mon, 24 Jun 2019 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anti-trust]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[cat and mouse game]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evade]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[ooff the cuff]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[price-fixing]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[wrongdoing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9601</guid>
		<description><![CDATA[Many are already aware of the critical factors that make generic drugs so important for patients &#8211; virtually for all. These don’t just facilitate greater access to health care &#8211; offering affordable alternatives to high-priced off-patent innovative drugs. This is &#8230; <a href="http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Creative Is Pharma Industry?</title>
		<link>http://www.tapanray.in/how-creative-is-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-creative-is-pharma-industry</link>
		<comments>http://www.tapanray.in/how-creative-is-pharma-industry/#comments</comments>
		<pubDate>Mon, 15 Apr 2019 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[creativity]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[gross]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mother]]></category>
		<category><![CDATA[necessity]]></category>
		<category><![CDATA[Operating]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9482</guid>
		<description><![CDATA[“Because the purpose of business is to create a customer, the business enterprise has two – and only two – basic functions: marketing and innovation. Marketing and innovation produce results; all the rest are costs. Marketing is the distinguishing, unique &#8230; <a href="http://www.tapanray.in/how-creative-is-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-creative-is-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing Pressure to Escalate Further?</title>
		<link>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-pressure-to-escalate-further</link>
		<comments>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/#comments</comments>
		<pubDate>Mon, 12 Feb 2018 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[Central Medical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalate]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Progressive India” report]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[“Healthy States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8849</guid>
		<description><![CDATA[On February 09, 2018, NITI Aayog released its “Healthy States, Progressive India” Report. The study ranked the States based on ‘health index’. Kerala, Punjab and Tamil Nadu featured as top three in terms of overall performance in 2015-16. However, the interstate variation &#8230; <a href="http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Relevance of Content Marketing In Pharma</title>
		<link>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-content-marketing-in-pharma</link>
		<comments>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/#comments</comments>
		<pubDate>Sun, 11 Jun 2017 23:49:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UDFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8268</guid>
		<description><![CDATA[“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number &#8230; <a href="http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Explore the Emerging Markets with the &#8216;Wings of Courage&#8217;.</title>
		<link>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=explore-the-emerging-markets-with-the-wings-of-courage</link>
		<comments>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/#comments</comments>
		<pubDate>Mon, 07 Mar 2011 00:30:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Courage]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Explore]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Wings]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=293</guid>
		<description><![CDATA[Overall growth rate of the global pharmaceutical industry is currently hovering around 5%. Similar situation has been prevailing since last several years. There is no indication of acceleration of growth rate from any of the top 3 regions of the &#8230; <a href="http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
